Targapremir-210 is primarily utilized in the field of antiviral research, particularly for its potential in targeting specific RNA structures within viral genomes. Its application is significant in the development of therapeutic agents aimed at inhibiting viral replication, especially in RNA viruses. Researchers are exploring its efficacy in disrupting viral life cycles by binding to conserved RNA motifs, which could lead to the creation of novel antiviral drugs. Additionally, Targapremir-210 is being studied for its role in personalized medicine, where it may be tailored to combat specific viral strains, offering a targeted approach to treatment. Its use in preclinical studies has shown promise in reducing viral load and improving outcomes in experimental models, making it a candidate for further development in antiviral therapies.